We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.38 | -0.84% | 44.60 | 45.19 | 44.40 | 45.06 | 5,172,442 | 01:00:00 |
From May 2019 to May 2024
LONDON--GlaxoSmithKline PLC (GSK.LN) Monday said it has started a second phase study to evaluate the efficacy and safety of an antibody in patients with inflammatory hand osteoarthritis.
The healthcare company said the main objective of the randomized, placebo-controlled and parallel-group study is to assess the efficacy potential of subcutaneous injections of the antibody on pain. The secondary objectives is to assess the safety and pharmacokinetics of the antibody, the company said.
Shares at 0950 GMT up 2.50 pence, or 0.2%, at 1,508.50 pence valuing the company at 73.5 billion pounds ($104.66 billion).
Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter @OlgaCotaga
(END) Dow Jones Newswires
April 18, 2016 06:06 ET (10:06 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
